-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I9j4I7tIBoTZJeavUqAaLRYy/EENVoXXq5ThI+9f+DNJT5/Nt+MlMgbzyqKdToOp
 1LDqnjfm5w4t0gEGo+0Dww==

<SEC-DOCUMENT>0001130319-08-000373.txt : 20080505
<SEC-HEADER>0001130319-08-000373.hdr.sgml : 20080505
<ACCEPTANCE-DATETIME>20080505161350
ACCESSION NUMBER:		0001130319-08-000373
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080505
FILED AS OF DATE:		20080505
DATE AS OF CHANGE:		20080505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		08802831

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o40419e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 12pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 12pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>For the month of May 2008</B>

<P align="center" style="font-size: 10pt"><B>Commission File Number 000-31062</B>

<CENTER>
<DIV align="center" style="font-size: 24pt; margin-top:12pt"><B>Oncolytics
Biotech Inc.</B></DIV>

<DIV style="font-size: 1pt; margin-top: 0pt; width: 45%; border-top: 1px solid #000000">&nbsp;</DIV>

<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B></DIV>


<DIV style="font-size: 1pt; margin-top: 0pt; width: 45%; border-top: 1px solid #000000">&nbsp;</DIV>

<div align="center" style="font-size: 10pt; margin-top: 0pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>

<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date:&nbsp;&nbsp;May&nbsp;5, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o40419o4041900.gif" alt="(ONCOLYTICS LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="MIDDLE">210, 1167 Kensington Cr. N.W<BR>Calgary, Alberta<BR>Canada T2N 1X7</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; May&nbsp;5, 2008 &#151; </B>Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today
that its 2008 Annual and Special Meeting of the Shareholders will be held on <B>Wednesday, May&nbsp;7, 2008
at 9:00 a.m. (ET) </B>at the Yale Club of New York City, 50 Vanderbilt Ave, New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Following the business portion of the meeting, Dr.&nbsp;Brad Thompson, President and CEO of Oncolytics,
will discuss recent progress in developing REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a potential cancer therapeutic.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A live audio webcast of the presentation will begin at approximately 9:15 a.m. (ET)&nbsp;at:
<U>http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2266660</U> or on the company&#146;s website
at <U>www.oncolyticsbiotech.com</U>. It is recommended that listeners log on 15 minutes in advance of
the presentation to register and download any necessary software.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">An audio replay will be accessible following the presentation at www.oncolyticsbiotech.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>The presentation time is subject to change. This release and the presentation related thereto
contain forward-looking statements which involve known and unknown risks, delays, uncertainties and
other factors not under the Company&#146;s control and which may cause actual results, performance or
achievements of the Company to be materially different from the results, performance or
expectations implied by these forward-looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN</I><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company&#146;s quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The
Company does not undertake to update these forward-looking statements.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cathy Ward
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Erika Moran</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">210, 1167 Kensington Cr NW
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">325, 300 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11 Stone St, 3rd Floor</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Calgary, Alberta T2N 1X7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Calgary, Alberta, T2P 3C4
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10004</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tel: 403.670.7377
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 403.538.4845
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 403.283.0858
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 403.237.6916
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> <U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-30-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o40419o4041900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40419o4041900.gif
M1TE&.#EA'`%``.8``)"-B_[^^_KZ^?S\_,&\J(%Z7P\,#?W]]>CGY7YW5_[^
M^GAS<MK8UO3SZOO[^F1=,\?&QJ>DB61=.L3`K?/QY&EB1;NXI/GY]JRHD_K[
M[/S]^69=0K>SFOWY^\G&LO[\_/7T\O'OZ9F3>HF#9V1@-=33NE!-365@/&IB
M.^SIWN#=U'%I2OK\^?[^]_GY\/S\^/GV];"MFOSW^92-=OS]_/S^^J.<B_S]
M\N3CTNGFW8.`?6EC-?W^_G=R3='-O,"]N5]8-?K[]>'@S/W]_=72P_+RW_[\
M^M[<RG=N4]S;Q/S^]^+@W*>CH-/2T)"*;6A>._SZ]?K\\;.NJ-K6R_SZ\>KJ
MUO;W]*2@@&9B+V=>-<[*QMC6PV%<+X1_6_K\^_G\XVED8.CFU9Z9??W[]_OY
M^_W\_6]G0?;WZL&_I'!J-&!?,VMF/??YYYR7<N_NVV57,N_NXF%8/O?V[["M
MCC,O+____O_^_O[___[__?W^_^GHV>?GT/#PX,_-LO[^_O___R'Y!```````
M+``````<`4````?_@'^"@X2%@W5UAW9^C(B.CXQ^=HE_B(:7F)F:FYR=GI^@
MH:*CI*6FHH^.>`$!=JZOKZQXJ9:GMK>XN;J[O+V;=7C!LXZPQ9./PK.^R\S-
MSL_0AHR"?@H*K79#L:S<K$,?VMK5UI33T>?HZ>KH`P-^0]\=[O!&4%,3^/GY
M36-&'^#^/KSSTVZ=P8,($X9ZU\Y!APX?C`@ID:`'B@<8,V9\TF/&%A47.LB0
MU\Z<PI,H4ZHKXVZ``R@-)A18`80$"2XV<^K<P26+A`TS1*2`,F"('P=#5"I=
MRG2747<-T"0`<G$'QAT;LFK5BH6G511/S(A)\<YHT[-HTV)BQ,J/!@UG_S@D
MV+&#Q`D)$KI$P)"CKU^_):Y,Q4NB[@@+!X+`N\.*DMK'D!4&>*&!19`;/F:\
MR7)"S8D",SPL$3!@+3P&'F(4.-$YRY,9.%AXH:$@B(+(N'.G:^M`21^+*"2<
M2,"A010Y+_SP6-ONA9(;?.94D/#`=8(I<C0$**J[N_=E-!P,:,!A#98'0)!8
M.!/$A1P\`F@DO42PN9(743PX$?X`11PQ9PP@P'S?%6B@*3QH`(<80&"!Q0EB
MP$%:44.P$%YIF,@GWQ`..'`!"!A4<,(#3TAPA1P"^''@BBQN`H\?C*4P@U5O
MJ*=$`,I%HB,F=>A85E$L$#$#"EGX%`$?"MS!P_^++3;)HE'O:"#&"0ZN8($+
MLUU2BY:.$3);!E>L($%P<S0P!`\$J>CDFM\QXH`?1""!@DTX7#"`%RSD(I\"
M+AR1P`E$3G"426P6BIMR`Z@@YA-`<.""?"\$X`@ICVCP`@L#!(%!'"CL4,`2
M/*!IZ*AH/?+'$`,L`<8*8$5P`0MO73,,I8C@T8("=M)P@1-/O%$!&"`@94<E
M6Y)J+$(M'-!"*T90$0$*:JB!`0QD^-&8+K7<00,1/:C1'P%0=*"-`K<>:^Y!
M+2SKRAAA)/``"5T(0489UDJJBS)_W"%`%!&<0,(3":0@;`#+GFMP.L&X4H<+
M<TB0!0E)G"$`&4-<F\O_-8D0%$0&(JSQ@`0C'/!*L0>7S,P=DMB!1Q7N[G!%
M$0=<4.TJ7=IRZRQ^7/"""T2L\,`:%4R!C2LF%\V,'V4DW4+#60"QQPT*0!E,
MS:?<*JF.`7@@P1HHB"!'&481:/38N:!*4!1FV-4&U'@(8NK%"N#KMAM.8!0P
MJF:1K?<M99#A@`!;K$&"!!,L2\G;N-`R"!4E`,&%&1:("\_>E)N"M``7S/!N
MP!\0K?@NM"B0@7DD8$!#.V)7KKHG[\`0`A)6%0!#Y\-.2G+BCWQ`A00XC7!!
M`')0O?KPF!QPP!`Y/$&B#^X8Q`@!<61A1A$!T*!=`&TG_4$+-RC63@`:*#``
M_QD/C?3!&`IH,$"2KN!Q#4-6!!'%&0>$^]`',IAOQT.A\H!'?>63P3_L\`&(
M%'`D^9/<`;Z0B0Z,H04%%$BZ[H`)&'3`@E#(0`8.X`#:7",`2I"#%2YPF18$
M00X*V-D!;A`J>.#O'^(:P`MJ$X33E8$&C1E"TA1P`RI`L`-V2->M'!(`9>&O
M`R$!1]+@`0.D%&50@^"!%P2PP@/`('\R"$(0-&`%+UR@BS1(5AER8`8L2(`(
M;W+>`*:P@BR@(`8XBA3V_C`O.4R``/A005%.!X^DR4`+^:#`#._0OFMD`W,7
M.``;^H!'`G#@"F@@@`>@X(`R?*`,H>H1T@S8`1=L`?^/$T"#*/&XA0R,`7/R
MR\0=)X"#SA$L216T0".3$+,!!<`:"A#`OI(0R0DLP0ID&$`4A`!*?$22`,C$
M!P%ZB4<5R+$.J$K5*AD@$'+%[1\?8(7?H'"&"?S`FS\(YP\:``4KH,H!%*0&
M?FYP`Q?<<0X)$,$=/6"<(#@`?1IP@`VHTP4X:,-Y0X!"`=SH!'<(0!9_`%L(
M*A"'NR3@""\`VSQ>@H0-2*`"0K`&(56V"E=<P`$-.((3Q"2!)Q3&+BL0@0ZT
M,(8!9-(/-NP`'))PA1X(AS5VV0!'G#"!%.@L")EH8Q;0T`([W!(/Z32$#&PP
M'0E\ZE4T<%\+\-`!,E2A6QO_0`("JBI#"U@4+WA!3W48*J(*9*4"L6D,TH9`
M`*U$P`Y&."HA!U#`#AQ`"'UP`FOV*APSC&`&`&#`!01`"#^,80IB$(%>:Y(&
MUFR@`DY0K`]N$`"D%.`B3C@`C@#:@H%F808#,`(.YYBT$&R@,W9)``Y>@!28
MWO-9*#@!#K1SAT0``WMXR$`5F!H',ZQ@#C&8PQPXP($10#8$<G`I#WHT@%LN
M809W,8,38D#=ZL[!#,)Q@@?X<(-,E!$+:+A!'6YY.T%T``HBB.T&G)`#%VB`
M!P2#3PH*4!,DZ,$A\E!`$JI+7>&2H#HCX"\&I"`%%]1`K6`C0`50L($(O.`#
M4W/%_Q`>$H(8K.`N)QB!<#$PW#"M@`FD2:,@'$"$#:QA!RN(`'7[(-P(K.#%
M"1`"96]YV1TXH07O,`@\6I"`+#Q@!@3A1MO>08$X2*`'/2"!&N(%A3)(3@%'
M*)($<-!<9=P!#THP7A56\-@5A(&=QO-ALJP!A4AE\@X:B$(#G``$O])R6?\8
MPQ@.4((1[+4';AC(<@CQ70O<0&4!T$1`V1`!(*SA,S*F08):4`4D5`!@*E`"
M#?RP"G(MZY;)RH##GA`#:X"O+0,8K28U0`!_H2`"4.A<(NSP@A>,`0X%H`[(
M,D"N`]0Z7;>9!R&6P*D'C.`+-W@!#6@0A1M$8851H,`-,O^`/3MX=@9)4I,Z
ML-?9(LT`>V?"7AT80X$1K6$.7=C!&GI`!'_H\`-3<)@$PL!11`CH`!E(0@].
ML`$1P,%PL,@F*SP=JC_XX05NZ,+65E"%,8@+FSHT+`5&L+431$`\0Z!!(59@
M4C0H8!&!;J"U&C"'G/0@"2YXP0&.T`.?%$`%D\!EW(Q!,(MRFA4;=85R&K-M
M!:"!!%C(0@2*>@P"RD$((]@!%GK0AP8X(!E(QX0*B$0")]#Z!?&AP6QH`*LH
M:!%&"GAVM`U"[6=C&[ZS8$P13K"#1GG@!#[N@0K&H`$GJV`#/F$W,&91!@<$
MH0H"KP`2IJ!9.]R!,;CL!BOZ?0?_!91``G81`14*^`U/A[H,!X">63=`H<D-
M@N)/($`KK*4)'K"$!@V(0%T`=@2>%<`F"5`!$/]P2UDM(F5&;8'+8W`S1%Q9
M`?"5U+9;</.<[UQAP9@S&A[@H#9D0``=4+G*,VZ(!F!@1"L00Q^(T(`;6"8^
M+,A^9;"N]?]QW59>QT.HM%WXL9,`!1R`PK-XT@,A1,$!'WA[W!&A[78$00@G
M>,(&$@`'!="_]1\D>#Q`07Z@!"*`<R30!XL'#I9V*UY0,5N@4V;P!$W@!011
M!H2P`CN0!01P<:N@"<HQ(/#F!$3R!"O0!PFP`0_0`SC09+:5"NY3!Z[0<B45
M`S<P5;5"_RY*HGNVTGLZQW.VT@+C(0;$1P)BX`(6]'=*N(28<`=D8`%)=GYQ
M,`,1$`%HP`<4(#];Q`+<9VUQ(VV[`7[6ACW],PNV4@0WD052D#\B0'P[T`-[
M\`(=P`!P]P![("FRP"$W$`%JX$9MP`=48(9+8@PS.(#^=@`;T"`[\`490$"N
M!#Y1P`-%T2Y9D'-2D`>2*#;?152`I@E4ERQ01P57D`4;^`9X85\FA#&P``SD
M,C0*,'LM,&D*,UY*X@?T=P"]1P(1<'&QUP)&$`(%\`">@0,N<`'*T3_(N&?2
M,!M18`$CD!7*\U\GT`-SL`7*,@8?L#X%0!<W)A\&$1X\E@5<(/\"`=`!&J`$
M2N!_8N<O)\`!UW`&5Q`MGH(#5'`$3Z!_.?`!XX4]9;`O5R"%X&(4//0%FC4T
MV#1'_M8"7:`&7;$'8Y`_'V`-$1$%\N$'<G`%RB,!4M!:8)@&9M2!"O,'KW`(
MP&"+?W<4`@`"3!`'7,`%604"K+`(5#->FD5!1F51)$![U^`VP("..'@'O&<3
M#C<0=U`#-7`#`6<5&Y`#`J1O@O>4W6`$"?0!,-``1%``"<!E.D6*:Q`#,D`0
M64<D,W`#+O6-+-!9[S(#-)"-Z*B.`6!^)V`!XJ<!1=`O0.!4;F"//Y&/XX54
M1>$")>`MTD4!1,$"-:`$N`:5;7.();#_`PSI=.+"0S>X+$/@-T2@/%:!`$[4
MD1^I+B4)"\0B-P/A!R!@`^+X4';@:<-R"003`#;YBHBGDQE7*X?YDT'Y(!%`
ME,.F``LGE$D@![,#E<*Y;ZDF`#.4+,8#!U/P`TA`=ESP!#^@0RQ@`6C7`V'P
M7F9)`3V&`J!5F31P8-OVENQH`76P)%&0`5/"!4"0`'U0(DNICU/#(4&P!SU@
M%0]U`QH03=]IE/QIE'&3,4%0`OZB!G`H'@1C-:AS`'VP-=7!(?`@-FF0!1L`
MDC,(>[4S*=2`*BEB`1=1`!00A*VP%LM"0;:B@CEI-3R)!]^I;3V(@+O("$J"
M)C#@`17`$VUP_P8P\`W8M*/#J0%!D(Z4\1:M=D5C4`1MT!-Q(`71E`/JY@,L
MH(SI0`-!X`%/X$8>\`Z8Y#\U!Y=R.028XP(N$`$D<@)M,#@;P&Y34P?OE@%]
MP#6L40(W``4!<$/]V9__Z6]!0&@G(#@1X`+-U1;O$``9M%@HT`9*F&.#,($3
M2CLSR`VVR).$\*`#P`$7D0`?FBXA2A_74%L!<`,C@@6RF:)E"`RWJ8LX]G>A
M0BURP`&\0P)SP`9&0(C9()P*0#^VIJ'CPP(7<`%N(`)%4@%:@#0#D`-PEP46
M$`10B@YA%`%X40$'4`?@@(G!<$MPR0$M@"JMMC-BL&`,.3AA4#%6YO\'\A-O
MV,4:'+`%+@`%[,1.9S`%4W`&B#D,=?`"RW8%G=&.*:`LMZ(`RN(&+O83(L`&
M.88R?/83&#"9Z0)FF!HVTC801F$!F\,'J=D6:U$#`UAXGFH3.BEQH<D#TFHM
MO$<EIDIIXN=Y$*%^>SINV"%$Z2('*C`%*F`-X;-OH;<%);`%*7!LRK)%<B`"
M>RH!EOH.*3D"55H`D6@0&G`#<4`B2.`"?O`!9""MX/,"1>8O''`#Z6@-J^!\
MCH,%:K!N!X4O[F,-+8`#,S`=(Y(`:ML#"=`%*1@'5^`&+?`(S:5F$3`7)[`"
M6%D`?%L`2#`5%5``V$%8F."193<":INX:EO_`"-`!*=3+9A@`:3HH0J#J-)@
ML7]W`%&`>!(0`[8V:1V+B;<D0PIF%SM':0$P?HR:!",0'''@MHNKMED!!EKP
M`D%@N[B"`3[6'VS;`VZ+E2/04!+@`5FHH0+`!$^P`V:P!1RK#AK@!D2R`3&0
MGTD#7Y[F!\#(MT05>-!$!B`"NP60`K>T45<F*7;@$D&``VC@!&KKMK\[!WCD
M`2E``XX`4QIR`!2@!3/`MVV[`K_;!6+@`T3Q19DP`OS;MWS;!5W`MR)P`"]@
M-IC@`5@I`@WP"I9WN5&U"@=@P`5``)^K(K4R?IY6!A*<``5@`3BR"N/7"MAT
M`UL@&`C,MX=!`!:P_P1:]!:6<@_+-`-MFP!FP+9N:X4E4$->\`$"H%`H@!,3
MD*SG$`1H``0UH@5!@'QG4@/IH@$=X``A0`%%<`9(07-_(``@Q0=8R`=!L#X;
MY3[8\#<DU`)%@(5%0`$A,,=6L$0=`@D#`#9E(`,P``(AD`)_3`1P0`$4P`=G
M`'54E`&9,,=SW`".[,A<3`&.K#XE@0D7$,E`!)KT89380P,O,,A\T`"VUCPA
M;,7I,@`7U`!R#`*+D;IH,C0"=``-P`>,[,AS?`&U82FQ`C[:$5<-$`)P``<6
M0`2,[`(WP!Y1H`3?X`?D$VY<4`%>8!`J4`$DD`4)T`",(`-D<)C*@@??8/\'
MZ,,(1".2(,1%I+$80\`^*O,^0S`;.@01Y2,`H:)+5*>K]%N21\P2\FR[K?:D
MR(=%'="/0?`%#(0)#P$14.(CQ^@'`Y)4A3!A36E4.UFQ!X8RBU`QB:$^25$K
M()1E"O`.<89-?N?*VA"3(B$2WSP$7ZE#96`$0HK#5H,F'10J,3ILBC8$2200
M2](*%D#-)#`!$34OUD0#>9`+>6#%7P@#%S`&?+@#<9D<2X(FC(`S*1,)A"!S
M#ML(,"*#?O=WKZ?0XJ#0D0`)DB#6.O*@KX<'X9,)VO#59CT(?X<)V7#1[>/0
MA1`))^EO*4,S/*E)4\T(VB"#*7.2X@P+95'5X@#_)9J$,CABU2@#HY$0*M-0
M%C$Z"PW0NER0`#E@!"Z!2QYKU!YT.DA$<H;6`RF0)'F0!V!(/*QM")4]KV?W
M`'$I,0Y`AI^-"YCH/UXZ`&%*`FO0*`>`5*F]VJU=W/DR?JL0`@('!"M0`E``
M)4J8"X?J!T8P!D*0`,*1`&$P57<PW,;]W=1@O=6C`1Y@8KX6!DX+V;D`(VRA
M`&'0!6Y4`4F0`<G1W:I=6"$``?H-`<&*(6N!-!<``59@UW?](OD-`6\]")'`
M`/N]WTW`))A@!5K0X`Q@U?0!)7_0!/H-`L1="""`X&F"`!#`X01>"B*.`#!2
MXJ=R`4W0!&4Q!$NP!/^]_R-^H.$0D-!LK2/?>0T\0`-PP&9`\`0C0`4A(0\=
M3@J2^!!0``=RXA,SX`('H";1/0@#\`,&0`<````F8`((D#J#D")#``,+8`!-
MH.*"X*4Z8`)@``!TL.404`9>\$1P710#(`59;@`&H`,`8`-VXN6#T`17GN4`
MP`1R?@D<@@!;;@!9CN*:<`<08``:.@0`8``_0"BG,.D`D.*8D"IT0.:ZI`5T
M``;_W0ZILN58#@!/=.1'X1)O\IW+TCIRL!]X8:E-!C:YH,<9)`)5:@8V(`=0
M\`X45(N$4.4&``9VX`!,@.6JWB$"8`)D;N:G,N8Z(,8@0`-@8`!2L*M(`==W
M(/\@`B(`G9X#="YBEP#H6F",(#!8*8()#M`$;?X'\[#NF>#HBJ[MDU[I1SX*
MDZX#FGX)#K`$6$X'=(``5B[J].%%`:[H*A(>("#&?DX-18$RKO[1$_8!>I``
M]XA^.<`A_FT+3C8$*C`'K"(!>R<^`_$'\`6&`F#E=*`#:9[G",#NXG$!SE[F
MFN`%UPYB?S,`^\[0S4,-P]8A+M'I2]`.`Y+O#%#L"^#R@B7OAF`%.J#H+N'P
M^9XOCPX&+K\`SH[ON8#I_6X(G,X$[FX"4A#JS#$@3"#UI&$G[8"!]-$A'0)3
M2$U7_]`"',`J6?`?*5`&JWD+.K0$3K"T*+`"/H"-X-#_/"E/"`Y0\`-`\`+?
M!&L!]S4/[=@;ZA`0`@R^`'2@!4O"'1!?>>!N`$5/+S]_"5I@`$S@X!]UY$.`
M`-<N!9</`2[>Z(\NQHQP[Y9N"CT?UX8.\$S@!Q"P`&`P_)B`-T/```*OWPBP
M!"/N^=)PX#`P<]A&.T7$`6;`!<$A`A1P/`G=#;3@"-T`V&#S:B-0$SN``CXP
M.]E`+]1`*'Z@`@(/`"ZO`R'@(GXPZ0_>\7?M!TP`"#HZ"PN"30-^?G^+BWY#
M?T,.`S`Z!@@##D-WCXR=?UIT!J(&)A>*GHR:(()T@TRHG0-#$`9#CGXV!DME
M`["^OXP`=#\#`W>_"'12?@X\_Y4+P(E#"((F)H((FKX#2ZTAOP$M&1X262A9
M$AXN02\"#AI&1C1U]/7T?AKY&B\7`OX>/=:0(+&FQ(L/IX!!<F!E$XA,VA3Z
M`2%`UC&%?P18R900V)`A`QYV_"6`HBP_5@;0P/AGX@5;(QEM&G`!1">4-#ZR
MW#E14D14S"YP='#!"B>%/")9H7BA6$Q&#D(,$?`KWP$789QL*)>EBX<B5`*4
M^?"A@YVS:-'&B_<"2@,+!5"H`2+!21\J8P0<!58,4Z2*B3`R<V>+)2:.+*=F
M0L32`420AY]Z\B/@Y<_)/!RXZ_27\4Z,G0/#^IA4EF//$@]KG@K2ER,0%U;Z
M"J"!1O^'#@A$5'B0Q9S=!@INFTV+=DB'#U#&P/'@Y(0$+&I.1.#S0H."%[(5
MGG8$$G#B2#H%#ZC8"[0D29(]@?3C]&]Z1MQ57D0UA$;%O7]RHO\,>CQJ]7W9
M$HDCADTEBRP\R+)-4.7!0ML`'9!1!AP<H/#$#KU)(((-'E``10`@A@CB!S*$
M0(`-3DCPP`-8[-!##&>\((L2001@V$F#(:;0'93)@I]K386WHT\.O)>*--(X
M)=AB1?KRT6HW0588?[^P1YAD[&'"'DB2?#=>4HO]R(A>COV"!QYU_&''!T9`
M<8$-2#PAYQ-`G',%&A/DJ6>>$4A`YQ,/K&$.!C?<H$0`9^+7H4":5#;JZ*.0
M1BKII)16"ND==RC:@@)B?3!&`QC$40$09G"!!1<KIIHJ%JP^8(8$*VP@@@H.
ML$"#B"`R:NFNO/;JZZ_`4IH'#SPH8.P+`7Q0!AE6J$#$"$B<H,9`U%8[$!!K
M((&$!RK`0`8-X'K!`Z;D!FONN>BFJVZCP_*`1P`O'#O&$+R\<,`9$UC@A+;\
M]NN$!3ZX@"P-#M`0A1(T%$,NINLV[/##$%N:B!^8!J#`NP'`-$2(&H20PL<@
<?YQ#"&5,[`<-?H03`'LT+#Q?Q##'++.Z@0``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
